NanoSyrinx wins award for “Best Innovation”

NanoSyrinx has been recognised by winning the award for Best Innovation at the ICURe Celebration & Showcase event, held at County Hall, London 22nd March 2022. 

The award panel, comprised of innovators and early-stage investors, recognised the groundbreaking nature of the company’s technology and commented on its potential to have a significant impact on the biologic therapeutics market by creating a whole new class of targeted medicines.

Joe Healey, CEO, said:

“We are delighted that NanoSyrinx has been recognised with this award. It shows how far the company has progressed, since completing the ICURe programme in 2018.  ICURe gave us a head-start in terms of validating the market demand for our technology and also brought us together for the first time as a founding team. The experience has stood us in good stead for where we are today, and I’d recommend that anyone given the opportunity to take part, does so.”

The award was presented by Andy Street, Mayor of the West Midlands and former Managing Director of John Lewis, alongside Dr Laura Lane, Principal at Advent Life Sciences and Prof Stuart Croft, Vice Chancellor and President of the University of Warwick.

ICURe, which stands for Innovation to Commercialisation of University Research, is a 3-6 month customer discovery and business planning accelerator designed using lean start-up methodology and funded by Innovate UK.

The programme trains, funds and supports teams led by university early-career researchers (ECRs) to determine whether there is a market for products or services that utilise their research, science or technology.

Read more news

NanoSyrinx at Number 10

Our CEO Joe Healey was invited to Number 10 this week, to discuss the future of Engineering Biology in the UK as part of a networking and investment breakfast. Synthetic biology or “Engineering Biology” has been highlighted as one of the five key technology areas for the UK’s future economy. Understanding how best to incubate, […]

Read more

JPM week 2024: NanoSyrinx highlighted in GEN

NanoSyrinx CEO Joe Healey, and CBO James Lapworth attended the JP Morgan Healthcare conference in San Francisco last week. Among a great week of meetings with collaborators, investors and partners, they sat down with Jonathan Grinstein PhD, a writer for GEN Edge, and spoke about the journey the company had been on and the outlook […]

Read more
Anthony Johnson, NanoSyrinx NED

NanoSyrinx appoints Anthony Johnson as Non-Executive Director

Coventry, UK, 10 November 2023: NanoSyrinx, a synthetic biology company developing a novel platform for targeted intracellular delivery of biologic therapeutics, today announced Anthony Johnson, M. D., has joined its Board as Non-Executive Director. Tony’s appointment forms part of the Company’s ongoing strategy to expand and strengthen its leadership team as the Company prepares for […]

Read more